Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Mississippi Attorney General Hopes Pharmaceutical Settlement Will Fund Mental Health

By Pharmaceutical Processing | March 11, 2011

JACKSON,
Miss. (AP) — Mississippi Attorney
General Jim Hood said Thursday he hopes that lawmakers will use $20.2 million
that the state received from settling its lawsuit against pharmaceutical
companies to fund mental health programs next year.

Hood, a Democrat, said the funds would address the mental
health care “crisis” that prompted child-services advocates to sue
the state in 2010. He said that increasing funds for community programs could
prevent similar legal challenges in the future.

The Southern Poverty Law Center in their ongoing case
charges that Mississippi
fails to care for low-income children with mental illness. The plaintiffs say
that, in order to avoid further lawsuits, the state must shift funds away from
large psychiatric hospitals and toward community care.

“This $20 million would go a long way toward filling a
hole that will help protect our citizens from people who are mentally
ill,” Hood said. “Law enforcement certainly does not want to see
people who are mentally ill locked up in jail. That’s not where they belong,
and that’s what’s going to happen if we don’t spend the money now.”

House Appropriations Committee Chairman Johnny Stringer,
D-Montrose, agreed. He said the budget for the year that begins July 1 just
happens to be short $20 million, and the money would help support the state’s
15 community mental health centers. They serve residents with intellectual
disabilities and mental illness.

“They don’t deserve to be put in jail,” Stringer
said. “They’re not criminals. They’re just sick like someone who has a
heart attack.”

The Southern Poverty Law Center charges in a suit filed last
year that Mississippi
fails low-income children by funding large, ineffective institutions rather
than providing services in the communities where patients live. The complaint
says that institutional care can often be “counterproductive and
harmful.” The case is being mediated.

Sheila Bedi, the deputy legal director for the SPLC’s
Children at Risk program, said the problem comes from how the state implements
its program, not solely from the budget gap.

“Mississippi’s
mental health crisis is not just about a shortage of funds,” Bedi said.
“It’s about misaligned priorities that focus on institutions at the
expense of community-based services.”

She said that for the state to minimize its liability, it
would need to reduce the number of beds in institutions, besides increasing
funds for community-based centers.

A state Department of Health spokeswoman, Wendy Bailey, said
the settlement money would complete the state’s Medicaid match for the
community center program.

“The CMHCs help prevent individuals from needing
lengthy inpatient care and serve patients who are discharged from private and
public hospitals to ensure they do not need to return to a hospital for
additional lengthy inpatient care,” Bailey wrote in an e-mail.

The new funding comes from litigation that the attorney
general’s office recently settled with four drug companies: GlaxoSmithKline
PLC, Aventis, Schering/Warrick and Mylan. The suit came after allegations of
Medicaid fraud and consumer protection violations related to inflation of the
average wholesale price of drugs.

After other states began settling similar suits, Hood found
that some companies had inflated prices as much 1,200 percent in sales to Mississippi’s Medicaid
and public employee insurance programs.

At $8 million, GlaxoSmithKline’s contribution to the fund
amounted to the largest sum in the case. To date, the attorney general has
recovered $47.9 million during the fiscal year that started last July 1.
Settlement funds totaled nearly $128 million last fiscal year, and more than
$500 million over the course of Hood’s nearly eight-year tenure.

“There are other companies that we still have out there
that we’re still litigating with,” Hood said, adding that he hopes for
more settlements.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE